Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Depreciation & Amortization (CF) (2018 - 2022)

Cyclerion Therapeutics has reported Depreciation & Amortization (CF) over the past 4 years, most recently at $100000.0 for Q3 2022.

  • For Q3 2022, Depreciation & Amortization (CF) fell 83.33% year-over-year to $100000.0; the TTM value through Jun 2023 reached $100000.0, down 87.44%, while the annual FY2022 figure was $65000.0, 86.23% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2022 was $100000.0 at Cyclerion Therapeutics, roughly flat from $100000.0 in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $800000.0 in Q2 2019 and troughed at $48000.0 in Q4 2021.
  • A 4-year average of $415200.0 and a median of $525000.0 in 2019 define the central range for Depreciation & Amortization (CF).
  • Biggest five-year swings in Depreciation & Amortization (CF): grew 19.24% in 2020 and later crashed 89.79% in 2021.
  • Year by year, Depreciation & Amortization (CF) stood at $653000.0 in 2019, then dropped by 28.02% to $470000.0 in 2020, then crashed by 89.79% to $48000.0 in 2021, then skyrocketed by 108.33% to $100000.0 in 2022.
  • Business Quant data shows Depreciation & Amortization (CF) for CYCN at $100000.0 in Q3 2022, $100000.0 in Q2 2022, and $48000.0 in Q1 2022.